All In Biotech

Drug Trial Radar · NCT07184827

Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated rUTIs in Women

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated Recurrent Urinary Tract Infections (rUTIs) in Women

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 348 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

348

Planned (sponsor's estimate)

Start

Oct 14, 2020

Primary completion

Jun 30, 2028

Study completion Jul 31, 2028

Sponsor

Sponsor type
Industry
First posted
Sep 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 20 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if drug U101 works to prevent recurrent urinary tract infection (rUTI) in women (≥ 20 and \< 76 years old) with a medical history. It will also investigate the safety and the impact on the Quality of Life improvement of drug U101. The main questions it aims to answer are: * Does the drug prevent or decrease the recurrence of urinary tract infection (UTI) during the 24-week treatment? * Will the Quality of Life be improved during the 24-week treatment? * What medical problems do participants have when taking drug U101? Researchers will compare drug U101 to a placebo (a look-alike substance that contains no drug) to see if drug U101 works to prevent rUTI. Participants will: * Orally take drug U101 or placebo every day for 24 weeks in the main study, three times per day (TID) for 8 weeks and twice per day (BID) for 16 weeks. * Visit the site once every 4 weeks for checkups and tests during the main study. * be asked to enroll in extensional study (the open-label extension (OLE) with drug U101 treatment or the Safety Follow-Up Visits with no investigational product treatment) for 24 weeks after they complete the 24-week main study. * Visit the site when the suspected UTI occurred during the main study or the extension study.

Conditions

  • Recurrent Urinary Tract Infections in Women

Interventions

  • U101Drug

    One capsule (100 mg) of U101 will be administered orally three times per day (TID) for 8 weeks followed by one capsule of U101 twice per day (BID) for 16 weeks.

  • PlaceboOther

    One capsule of Placebo will be administered orally three times per day (TID) for 8 weeks followed by one capsule of placebo twice per day (BID) for 16 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects without UTI recurrence during the 24-week main study periodTime frame: The primary analysis will be performed at the end of the 24-week main study

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Chang Gung Memorial Hospital, Chiayi Branch

    Chiayi City, Taiwan · Recruiting

  • Taiwan Provincial Yun-Lin Hospital

    Douliu, Taiwan · Recruiting

  • Chang Gung Memorial Hospital, Kaohsiung Branch

    Kaohsiung City, Taiwan · Recruiting

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan · Active not recruiting

  • Kaohsiung Veterans General Hospital

    Kaohsiung City, Taiwan · Recruiting

  • Taipei Tzu Chi Hospital

    New Taipei City, Taiwan · Recruiting

  • China Medical University Hospital

    Taichung, Taiwan · Recruiting

  • Chung Shan Medical University Hospital

    Taichung, Taiwan · Recruiting

  • Taichung Veterans General Hospital

    Taichung, Taiwan · Recruiting

  • National Cheng Kung University Hospital

    Tainan, Taiwan · Recruiting

  • Chang Gung Memorial Hospital, Taipei Branch

    Taipei, Taiwan · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

  • Taipei City Hospital, Renai Branch

    Taipei, Taiwan · Recruiting

  • Taipei City Hospital, Yangming Branch

    Taipei, Taiwan · Recruiting

  • Taipei Medical University Hospital

    Taipei, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

  • Tri-Service General Hospital (TSGH)

    Taipei, Taiwan · Recruiting

  • Chang Gung Memorial Hospital, Linkuo Branch

    Taoyuan, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.